Newron Pharmaceuticals SpA (NWRN) - Total Assets

Latest as of December 2025: CHF40.02 Million CHF ≈ $50.60 Million USD

Based on the latest financial reports, Newron Pharmaceuticals SpA (NWRN) holds total assets worth CHF40.02 Million CHF (≈ $50.60 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Newron Pharmaceuticals SpA - Total Assets Trend (2005–2025)

This chart illustrates how Newron Pharmaceuticals SpA's total assets have evolved over time, based on quarterly financial data. Also see market value of Newron Pharmaceuticals SpA for the company's overall valuation and market capitalisation.

Newron Pharmaceuticals SpA - Asset Composition Analysis

Current Asset Composition (December 2025)

Newron Pharmaceuticals SpA's total assets of CHF40.02 Million consist of 95.1% current assets and 4.9% non-current assets. Review Newron Pharmaceuticals SpA (NWRN) total liabilities to assess the company's total debt and financial obligations.

Asset Category	Amount (CHF)	% of Total Assets
Cash & Equivalents	CHF0.00	30.4%
Accounts Receivable	CHF6.16 Million	15.4%
Inventory	CHF0.00	0.0%
Property, Plant & Equipment	CHF736.00K	1.8%
Intangible Assets	CHF999.22	0.0%
Goodwill	CHF0.00	0.0%

Asset Composition Trend (2005–2025)

This chart illustrates how Newron Pharmaceuticals SpA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Newron Pharmaceuticals SpA stock price for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Newron Pharmaceuticals SpA's current assets represent 95.1% of total assets in 2025, an increase from 90.6% in 2005.
Cash Position: Cash and equivalents constituted 30.4% of total assets in 2025, down from 74.3% in 2005.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
Asset Diversification: The largest asset category is accounts receivable at 15.4% of total assets.

Newron Pharmaceuticals SpA Competitors by Total Assets

Key competitors of Newron Pharmaceuticals SpA based on total assets are shown below.

Company	Country	Total Assets
Tubize-Fin BR:TUB	Belgium	€1.99 Billion
Dianthus Therapeutics Inc. NASDAQ:DNTH	USA	$1.21 Billion
Tango Therapeutics Inc NASDAQ:TNGX	USA	$1.07 Billion
Damora Therapeutics, Inc. NASDAQ:DMRA	USA	$543.64 Million
Apnimed, Inc. Common Stock NASDAQ:APMD	USA	$342.63 Million
Wecome Pharmaceutical Co Ltd SHE:300878	China	CN¥1.49 Billion
Tectonic Therapeutic, Inc. NASDAQ:TECX	USA	$246.58 Million
Relmada Therapeutics Inc NASDAQ:RLMD	USA	$235.36 Million

Newron Pharmaceuticals SpA - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.76	2.60	5.50
Quick Ratio	0.76	2.60	5.50
Cash Ratio	0.00	0.00	0.00
Working Capital	CHF-12.04 Million	CHF37.60 Million	CHF30.98 Million

Newron Pharmaceuticals SpA - Advanced Valuation Insights

This section examines the relationship between Newron Pharmaceuticals SpA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	200.34
Latest Market Cap to Assets Ratio	6.09
Asset Growth Rate (YoY)	-37.4%
Total Assets	CHF40.02 Million
Market Capitalization	$243.84 Million USD

Valuation Analysis

Premium Asset Valuation: The market values Newron Pharmaceuticals SpA's assets at a significant premium (6.09x), suggesting investors see substantial growth potential or unique competitive advantages.

Significant Asset Reduction: Newron Pharmaceuticals SpA's assets decreased by 37.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Newron Pharmaceuticals SpA (2005–2025)

The table below shows the annual total assets of Newron Pharmaceuticals SpA from 2005 to 2025.

Year	Total Assets	Change
2025-12-31	CHF40.02 Million ≈ $50.60 Million	-37.37%
2024-12-31	CHF63.91 Million ≈ $80.80 Million	+147.07%
2023-12-31	CHF25.87 Million ≈ $32.70 Million	-30.46%
2022-12-31	CHF37.20 Million ≈ $47.02 Million	-26.33%
2021-12-31	CHF50.49 Million ≈ $63.83 Million	-1.39%
2020-12-31	CHF51.20 Million ≈ $64.73 Million	-15.08%
2019-12-31	CHF60.29 Million ≈ $76.22 Million	+0.48%
2018-12-31	CHF60.00 Million ≈ $75.85 Million	-17.84%
2017-12-31	CHF73.02 Million ≈ $92.32 Million	+29.04%
2016-12-31	CHF56.59 Million ≈ $71.55 Million	+27.51%
2015-12-31	CHF44.38 Million ≈ $56.11 Million	+19.71%
2014-12-31	CHF37.07 Million ≈ $46.87 Million	+17.26%
2013-12-31	CHF31.62 Million ≈ $39.97 Million	-29.18%
2012-12-31	CHF44.65 Million ≈ $56.45 Million	+229.11%
2011-12-31	CHF13.57 Million ≈ $17.15 Million	-29.09%
2010-12-31	CHF19.13 Million ≈ $24.19 Million	-54.10%
2009-12-31	CHF41.68 Million ≈ $52.69 Million	-31.16%
2008-12-31	CHF60.54 Million ≈ $76.54 Million	-13.97%
2007-12-31	CHF70.37 Million ≈ $88.96 Million	-18.33%
2006-12-31	CHF86.16 Million ≈ $108.93 Million	+266.67%
2005-12-31	CHF23.50 Million ≈ $29.71 Million	--

About Newron Pharmaceuticals SpA

SW:NWRN Switzerland Biotechnology

Market Cap

$293.03 Million

CHF231.78 Million CHF

Market Cap Rank

#15860 Global

#169 in Switzerland

Share Price

CHF11.14

Change (1 day)

+2.58%

52-Week Range

CHF10.28 - CHF30.40

All Time High

CHF30.40